# An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies

> **NCT04186637** · PHASE1 · TERMINATED · sponsor: **Alpine Immune Sciences, Inc.** · enrollment: 62 (actual)

## Conditions studied

- Advanced Solid Tumor
- Lymphoma

## Interventions

- **DRUG:** ALPN-202

## Key facts

- **NCT ID:** NCT04186637
- **Lead sponsor:** Alpine Immune Sciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-06-02
- **Primary completion:** 2022-11-09
- **Final completion:** 2023-02-28
- **Target enrollment:** 62 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2023-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04186637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04186637, "An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04186637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*